Novoteris, LLC., Medical Device and Pharmaceutical Product Innovators, Receives Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis.

Garden Grove, CA—December 18, 2013 (eReleases):  Novoteris, LLC. A clinical stage medical device and pharmaceutical developer focused on innovative applications for nitric oxide gas where it can be applied for unmet medical needs, announced today that the European Commission, Health & Consumers Directorate-General Medicinal products – authorizations, EMA, has granted it orphan drug designation for the use of inhaled nitric oxide for the treatment of Cystic Fibrosis. The European Orphan Drug Act is intended to encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders.  In addition to providing a ten year term of…

Continue Reading Novoteris, LLC., Medical Device and Pharmaceutical Product Innovators, Receives Orphan Drug Designation for Nitric Oxide for the Treatment of Cystic Fibrosis.